Nanosonics Ltd (NAN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Nanosonics Ltd (NAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013466
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nanosonics Ltd (Nanosonics) is a medical technology company, which focuses on the development of technologies for infection control. Its product portfolio includes decontamination products and accessories for the prevention of hospital acquired infections (HAI). The company’s trophon EPR is the next generation product in ultrasound probe disinfection. Trophon uses trophon chemical indicators and NanoNebulant /Sonex-HL disinfectant cartridges to disinfect the probe effectively . Nanosonics has a manufacturing facility in Lane Cove, Sydney. The company distributes its products through direct sales force and other distributors such as GE Healthcare, Regional Healthcare Group and AVA Medica, among others. Nanosonics is headquartered in Lane Cove, New South Wales, Australia.

Nanosonics Ltd (NAN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nanosonics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Nanosonics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Nanosonics Completes Rights Offering Of Shares For US$0.4 Million 11
Nanosonics Announces Private Placement Of Shares For US$16 Million 12
Debt Offering 13
Nanosonics Completes Private Placement Of Convertible Notes For US$8 Million 13
Nanosonics Ltd – Key Competitors 14
Nanosonics Ltd – Key Employees 15
Nanosonics Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Aug 24, 2017: Nanosonics 2017 full year financial results 17
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Nanosonics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nanosonics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nanosonics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Nanosonics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Nanosonics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Nanosonics Completes Rights Offering Of Shares For US$0.4 Million 11
Nanosonics Announces Private Placement Of Shares For US$16 Million 12
Nanosonics Completes Private Placement Of Convertible Notes For US$8 Million 13
Nanosonics Ltd, Key Competitors 14
Nanosonics Ltd, Key Employees 15
Nanosonics Ltd, Subsidiaries 16

★海外企業調査レポート[Nanosonics Ltd (NAN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fauji Fertilizer Co Ltd (FFC):企業の財務・戦略的SWOT分析
    Fauji Fertilizer Co Ltd (FFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Constellium NV:戦略・SWOT・企業財務分析
    Constellium NV - Strategy, SWOT and Corporate Finance Report Summary Constellium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Electricity & Water Authority:企業の戦略的SWOT分析
    Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Cohera Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cohera Medical Inc (Cohera) is a medical device company that designs and develops surgical adhesives and sealants. The company provides products such as TissuGlu surgical adhesive, Sylys surgical sealant, and others. Its TissuGlu surgical adhesive is biocompatible for internal use, and forms …
  • InspireMD Inc (NSPR):企業の財務・戦略的SWOT分析
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • Kronos Worldwide Inc (KRO):企業の財務・戦略的SWOT分析
    Kronos Worldwide Inc (KRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • GeneThera Inc (GTHR):企業の財務・戦略的SWOT分析
    Summary GeneThera Inc (GeneThera) is a biotechnology company that provides diagnostic services. The company develops molecular diagnostic tests, therapeutics, and vaccines to control emerging diseases in animals and in humans. Its products comprise Herd Guard, a Johne’s management solution; HerdChec …
  • Asda Stores Ltd:企業の戦略・SWOT・財務情報
    Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report Summary Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sierra Oncology Inc (SRRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small mo …
  • Kohler Co:企業の戦略的SWOT分析
    Kohler Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):企業の財務・戦略的SWOT分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Seven & i Holdings Co., Ltd.:戦略・SWOT・企業財務分析
    Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Enel Generacion Chile SA (ENELGXCH):電力:M&Aディール及び事業提携情報
    Summary Enel Generacion Chile SA (Enel Generacion), formerly Empresa Nacional de Electricidad SA, is a power utility. It generates, distributes and sells electricity, exports natural gas, and provides various energy related products and services. The company produces electricity using hydro, gas, fu …
  • UCB SA (UCB)-医療機器分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Ansvar Insurance Limited:企業の戦略・SWOT・財務分析
    Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Genting Berhad:企業の戦略・SWOT・財務分析
    Genting Berhad - Strategy, SWOT and Corporate Finance Report Summary Genting Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Viriom Inc-製薬・医療分野:企業M&A・提携分析
    Summary Viriom Inc (Viriom) focuses on the development of antivirals for HIV treatment and prevention. The company’s lead pipeline product candidate Elpida, is a bioavailable prodrug, and VM-1500A, a non-nucleoside HIV reverse transcriptase inhibitor. Its partner portfolio includes Roche, ChemDiv, I …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆